FDA Approves Remicade Biosimilar, Inflectra

Product is second biosimilar to win agency nod

The FDA has approved infliximab-dyyb (Inflectra, Celltrion, Inc.) for multiple indications. The product is biosimilar to infliximab (Remicade, Janssen Biotech), which was originally licensed in 1998. This is the second time the FDA has cleared a biosimilar product.

 


Our most popular topics on Managedcaremag.com